Neo-Mercazole (Carbimazole)

Carbimazole, the active ingredient in Neo-Mercazole, is a thionamide presented as an oral tablet for oral use. It treats hyperthyroidism, including Graves disease, and toxic multinodular goitre in adult patients.

GNH USA supplies Neo-Mercazole as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Carbimazole is used to manage disorders of excess thyroid hormone production.

Hyperthyroidism (e.g., Graves disease): reduces over‑production of T3 and T4, helping to control symptoms. Toxic multinodular goitre: lowers hormone output from autonomous nodules, improving clinical control. Relapse prevention after definitive therapy: maintains euthyroid status following radioactive iodine or surgery.

Carbimazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Skin rash or itching - Nausea or vomiting - Altered taste sensation - Arthralgia or muscle aches - Mild headache - Transient liver enzyme elevation

Serious or Rare Side Effects: - Agranulocytosis (dangerously low white blood cell count) - Severe hepatic injury or hepatitis - Vasculitis or cutaneous necrotizing lesions - Aplastic anemia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Acute pancreatitis

Before initiating carbimazole, several safety considerations should be observed.

Monitor blood counts: perform baseline and periodic complete blood count to detect agranulocytosis. Monitor liver function: assess hepatic enzymes before treatment and during therapy. Dose adjustment in the elderly: start with lower doses and titrate cautiously. Avoid in known hypersensitivity: discontinue if severe allergic reactions occur. Pregnancy considerations: use only if benefits outweigh potential risks, as safety data are limited. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Carbimazole can affect the activity of several other medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: carbimazole may enhance anticoagulant effect, increasing INR. - Lithium: concurrent use can exacerbate thyroid dysfunction. - Other antithyroid agents (e.g., propylthiouracil): combined therapy raises risk of severe bone marrow suppression.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of thyrotoxicosis, requiring dose adjustments. - ACE inhibitors: monitor blood pressure as thyroid status changes. - NSAIDs: may increase risk of agranulocytosis; observe blood counts regularly.